Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors (Q33393931)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors |
scientific article |
Statements
1 reference
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors (English)
1 reference
David Gandara
1 reference
D Ross Camidge
1 reference
Moacyr Ribeiro de Oliveira
1 reference
Philip Bonomi
1 reference
Divis Khaira
1 reference
Christine L Hann
1 reference
Evelyn M McKeegan
1 reference
Elizabeth Litvinovich
1 reference
Philip M Hemken
1 reference
Sari H Enschede
1 reference
Cathy Nolan
1 reference
Yi-Lin Chiu
1 reference
Todd Busman
1 reference
Hao Xiong
1 reference
Andrew P Krivoshik
1 reference
Rod Humerickhouse
1 reference
Geoffrey I Shapiro
1 reference
31 January 2011
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference